Cipla launches India's first inhalable insulin ‘Afrezza’

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management

Cipla has launched India's first inhalable insulin, Afrezza, after receiving approval from the Central Drugs Standard Control Organisation (CDSCO).

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management.

This breakthrough product aims to improve glycemic control for adults with both type 1 and type 2 diabetes who struggle with injectable insulin therapies. The inhalable insulin is delivered through a small inhaler, making it a convenient and non-invasive alternative to traditional injections, particularly for those with needle aversion.

Cipla's introduction of Afrezza in India represents a significant step in expanding access to advanced diabetes care in a country with one of the highest diabetes burdens globally.